CIBC World Market
CRSP icon

CIBC World Market’s CRISPR Therapeutics CRSP Stock Holding History

CIBC World Market’s Portfolio CRSP Stock Details CRSP Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$611K Buy
11,195
+627
+6% +$33K ﹤0.01% 1157
2026
Q1 		$503K Buy
10,568
+550
+5% +$29K ﹤0.01% 1124
2025
Q4 		$525K Sell
10,018
-1,934
-16% -$116K ﹤0.01% 1109
2025
Q3 		$775K Sell
11,952
-2,157
-15% -$124K ﹤0.01% 996
2025
Q2 		$686K Buy
14,109
+2,785
+25% +$108K ﹤0.01% 968
2025
Q1 		$385K Buy
11,324
+2,598
+30% +$110K ﹤0.01% 1098
2024
Q4 		$343K Sell
8,726
-2,638
-23% -$125K ﹤0.01% 1140
2024
Q3 		$534K Sell
11,364
-1,135
-9% -$57.6K ﹤0.01% 978
2024
Q2 		$675K Sell
12,499
-777
-6% -$44.9K ﹤0.01% 882
2024
Q1 		$905K Sell
13,276
-414
-3% -$29.6K ﹤0.01% 839
2023
Q4 		$857K Buy
13,690
+3,439
+34% +$190K ﹤0.01% 801
2023
Q3 		$465K Buy
10,251
+1,095
+12% +$56.6K ﹤0.01% 918
2023
Q2 		$514K Sell
9,156
-198
-2% -$11.2K ﹤0.01% 909
2023
Q1 		$423K Buy
9,354
+410
+5% +$19.9K ﹤0.01% 964
2022
Q4 		$364K Sell
8,944
-17
-0.2% -$902 ﹤0.01% 1002
2022
Q3 		$586K Sell
8,961
-417
-4% -$30.2K ﹤0.01% 843
2022
Q2 		$570K Buy
9,378
+1,024
+12% +$60.2K ﹤0.01% 854
2022
Q1 		$524K Buy
8,354
+2,760
+49% +$173K ﹤0.01% 919
2021
Q4 		$424K Sell
5,594
-840
-13% -$73.4K ﹤0.01% 1029
2021
Q3 		$720K Sell
6,434
-5,244
-45% -$659K ﹤0.01% 871
2021
Q2 		$1.89M Buy
11,678
+7,472
+178% +$909K 0.01% 609
2021
Q1 		$513K Buy
4,206
+1,954
+87% +$295K ﹤0.01% 960
2020
Q4 		$345K Buy
+2,252
New +$266K ﹤0.01% 1051
2018
Q3 		– Sell
-14,028
Closed -$824K – 1143
2018
Q2 		$824K Sell
14,028
-11,270
-45% -$642K ﹤0.01% 723
2018
Q1 		$1.16M Buy
+25,298
New +$1.04M ﹤0.01% 591

Other funds holding CRSP

AIM
ARK Investment Management St. Petersburg, Florida $15.4B AUM 50.29% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
OAG
Orbis Allan Gray Hamilton, Bermuda $29.1B AUM 60.8% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
GP
GSK plc London $602M AUM
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $153B AUM 38.14% 1-Year Est. Return
SOCM
SR One Capital Management Wayne, Pennsylvania $1.04B AUM 262.99% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return

CIBC World Market's CRSP Position: Q2 2026 in Review

CIBC World Market increased its CRISPR Therapeutics (CRSP) stake by 5.9% in Q2 2026, buying an estimated $33K and bringing the position to 11,195 shares worth $611K. The position accounts for ﹤0.01% of the portfolio, ranked #1157.

CIBC World Market first reported a position in CRSP in Q1 2018 and has held it in 25 quarters since. The position peaked at $1.89M in Q2 2021. 523 funds tracked by Wall St. Rank hold CRSP as of Q2 2026.

  • CIBC World Market held 11,195 shares of CRISPR Therapeutics worth $611K as of Q2 2026.
  • CIBC World Market bought 627 CRISPR Therapeutics shares in Q2 2026, an estimated $33K.
  • CRISPR Therapeutics made up ﹤0.01% of CIBC World Market's portfolio in Q2 2026, its #1157 holding.
  • CIBC World Market first reported a position in CRISPR Therapeutics in Q1 2018 and has held it in 25 quarters since.
  • CIBC World Market's CRISPR Therapeutics position peaked at $1.89M in Q2 2021.
  • 523 funds tracked by Wall St. Rank held CRISPR Therapeutics as of Q2 2026.

Based on CIBC World Market's 13F filing for Q2 2026, filed 13 Aug 2026.